C3 and paroxysmal nocturnal hemoglobinuria: However, eculizumab stochastically increases C3 expression in erythrocytes to mediate the formation of MAC leading to de novo extravascular hemolysis in patients with PNH, which reduced the clinical benefits of the treatment [142].